ALK and non-small cell lung carcinoma: Different strategies have been proposed to overcome TKi acquired resistance, including the development of next-generation drugs, such as the ALK-inhibitors LDK378-Ceritinib and AP26113-Brigatinib (for ALK-positive NSCLC resistant to Crizotinib), Lecitinib (for ALK-positive NSCLC carrying the L1169M mutation) and PF06463922 (a dual ALK/ROS1 inhibitor with a good CNS penetration profile) [123].